Welcome to this edition of The Prescription, which explores pivotal legal and regulatory developments across Australia’s life sciences, pharmaceutical, medical device, aged care and disability sectors, highlighting trends in patent disputes, compliance reforms, and the evolving role of AI in innovation.
We hope you enjoy this edition of The Prescription.
We consider the impact AI technology may have on the way validity and infringement of life sciences and healthcare related patents may be assessed.
Considerations for sponsors, manufacturers, and suppliers of medical devices to support compliance with the TGA’s new regimes.
We highlight the key patent filing insights and trends from the IP Report, for the life sciences, pharmaceutical and medical device industries in Australia.
We provide an update on recent criminal and civil proceedings against two not-for-profit NDIS providers.
A recent decision marks another victory for generic and biosimilar pharmaceutical companies in Australia.
Australia is undergoing a wave of sweeping reforms to retirement villages law.
A look at the two avenues on which Sun Pharma was successful in challenging the validity of a PTE for a formulation patent.
Challenges to patent term extensions remain a key area of disputes between patentees and generic/biosimilar drug suppliers in Australia.
Artificial intelligence has revolutionised the life sciences and healthcare sectors.